What’s New in HIV Drug Resistance
Sorry, this learning module is not available for mobile devices.
Daniel Kuritzkes, MD
Harvard Medical School
Presentation Date: 4/5/2012
Release Date: 4/5/2012
- 2nd generation NNRTIs.
- Integrase inhibitors
- CCR5 antagonists
- Drug-resistant minority variants
Daniel R. Kuritzkes, MD is Professor of Medicine at Harvard Medical School and Chief of Infectious Diseases Division at Brigham and Women's Hospital. Dr. Kuritzkes also is principal investigator and chair of the AIDS Clinical Trials Group (ACTG), and associate editor for The Journal of Infectious Diseases. Dr. Kuritzkes research interest focuses on antiretroviral therapy and drug resistance. He is author of more than 48 journal articles on HIV-related topics. He received his B.S. and M.S. from Yale and his M.D. from Harvard Medical School.